213 related articles for article (PubMed ID: 32555371)
41. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.
Liu H; Rich ES; Godley L; Odenike O; Joseph L; Marino S; Kline J; Nguyen V; Cunningham J; Larson RA; del Cerro P; Schroeder L; Pape L; Stock W; Wickrema A; Artz AS; van Besien K
Blood; 2011 Dec; 118(24):6438-45. PubMed ID: 21976674
[TBL] [Abstract][Full Text] [Related]
42. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
[TBL] [Abstract][Full Text] [Related]
43. [Two Kinds of HLA-mismatched Allogeneic Hematopoictic Stem Cell Transplantation for Treatment of Hematologic Malignancies].
Li WD; Gao ZY; Yu XJ; Lu DY; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):562-7. PubMed ID: 27151030
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation.
Waller EK; Langston AA; Lonial S; Cherry J; Somani J; Allen AJ; Rosenthal H; Redei I
Biol Blood Marrow Transplant; 2003 Jul; 9(7):460-71. PubMed ID: 12869960
[TBL] [Abstract][Full Text] [Related]
45. [Clinical study of double units unrelated cord blood transplantation in adult patients with hematological malignancies].
Yin Y; Ren HY; Cen XN; Qiu ZX; Ou JP; Wang WS; Xu WL; Wang MJ; Wang LH; Li Y
Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):73-7. PubMed ID: 18681304
[TBL] [Abstract][Full Text] [Related]
46. Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies.
Sanz GF; Saavedra S; Planelles D; Senent L; Cervera J; Barragán E; Jiménez C; Larrea L; Martín G; Martínez J; Jarque I; Moscardó F; Plumé G; Andreu R; Regadera AI; García I; Mollá S; Solves P; de La Rubia J; Bolufer P; Benlloch L; Soler MA; Marty ML; Sanz MA
Blood; 2001 Oct; 98(8):2332-8. PubMed ID: 11588027
[TBL] [Abstract][Full Text] [Related]
47. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation.
Zaucha JM; Gooley T; Bensinger WI; Heimfeld S; Chauncey TR; Zaucha R; Martin PJ; Flowers ME; Storek J; Georges G; Storb R; Torok-Storb B
Blood; 2001 Dec; 98(12):3221-7. PubMed ID: 11719357
[TBL] [Abstract][Full Text] [Related]
48. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.
Chang YJ; Wang Y; Mo XD; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Chen Y; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Cancer; 2017 Aug; 123(15):2881-2892. PubMed ID: 28301690
[TBL] [Abstract][Full Text] [Related]
49. "No wash" albumin-dextran dilution for double-unit cord blood transplantation is safe with high rates of sustained donor engraftment.
Dahi PB; Ponce DM; Devlin S; Evans KL; Lubin MN; Gonzales AM; Tonon J; Meagher R; Giralt S; Kernan NA; Scaradavou A; Barker JN
Biol Blood Marrow Transplant; 2014 Apr; 20(4):490-4. PubMed ID: 24361912
[TBL] [Abstract][Full Text] [Related]
50. HLA-mismatched haploidentical transplantation using low-dose anti-thymocyte globulin (ATG: thymoglobulin).
Kako S; Akahoshi Y; Harada N; Nakano H; Kameda K; Ugai T; Yamasaki R; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Ashizawa M; Terasako-Saito K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kanda Y
Hematology; 2017 Apr; 22(3):129-135. PubMed ID: 27905258
[TBL] [Abstract][Full Text] [Related]
51. Prospective Evaluation of Unrelated Donor Cord Blood and Haploidentical Donor Access Reveals Graft Availability Varies by Patient Ancestry: Practical Implications for Donor Selection.
Kosuri S; Wolff T; Devlin SM; Byam C; Mazis CM; Naputo K; Davis E; Paulson J; Nhaissi M; Wells DS; Dahi P; Giralt SA; Jakubowski A; Perales MA; Shaffer BC; Scaradavou A; Ponce DM; Barker JN
Biol Blood Marrow Transplant; 2017 Jun; 23(6):965-970. PubMed ID: 28263918
[TBL] [Abstract][Full Text] [Related]
52. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation.
Thomson BG; Robertson KA; Gowan D; Heilman D; Broxmeyer HE; Emanuel D; Kotylo P; Brahmi Z; Smith FO
Blood; 2000 Oct; 96(8):2703-11. PubMed ID: 11023501
[TBL] [Abstract][Full Text] [Related]
53. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.
Lekakis L; Giralt S; Couriel D; Shpall EJ; Hosing C; Khouri IF; Anderlini P; Korbling M; Martin T; Champlin RE; de Lima M
Bone Marrow Transplant; 2006 Sep; 38(6):421-6. PubMed ID: 16892072
[TBL] [Abstract][Full Text] [Related]
54. Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.
Baker M; Wang H; Rowley SD; Cai L; Pecora AL; Skarbnik A; Vesole DH; Adler-Brecher B; Kim D; Donato ML
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2047-2055. PubMed ID: 27522040
[TBL] [Abstract][Full Text] [Related]
55. Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor.
Magro E; Regidor C; Cabrera R; Sanjuán I; Forès R; Garcia-Marco JA; Ruiz E; Gil S; Bautista G; Millán I; Madrigal A; Fernandez MN
Haematologica; 2006 May; 91(5):640-8. PubMed ID: 16670070
[TBL] [Abstract][Full Text] [Related]
56. Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor.
Blaise D; Fürst S; Crocchiolo R; El-Cheikh J; Granata A; Harbi S; Bouabdallah R; Devillier R; Bramanti S; Lemarie C; Picard C; Chabannon C; Weiller PJ; Faucher C; Mohty B; Vey N; Castagna L
Biol Blood Marrow Transplant; 2016 Jan; 22(1):119-24. PubMed ID: 26341397
[TBL] [Abstract][Full Text] [Related]
57. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies.
Mavroudis D; Read E; Cottler-Fox M; Couriel D; Molldrem J; Carter C; Yu M; Dunbar C; Barrett J
Blood; 1996 Oct; 88(8):3223-9. PubMed ID: 8874224
[TBL] [Abstract][Full Text] [Related]
58. Cryopreserved CD34
Konuma T; Kato S; Oiwa-Monna M; Tanoue S; Ogawa M; Isobe M; Tojo A; Takahashi S
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1142-1150. PubMed ID: 28390987
[TBL] [Abstract][Full Text] [Related]
59. Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin.
Politikos I; Lavery JA; Hilden P; Cho C; Borrill T; Maloy MA; Giralt SA; van den Brink MRM; Perales MA; Barker JN
Blood Adv; 2020 Jan; 4(1):191-202. PubMed ID: 31935291
[TBL] [Abstract][Full Text] [Related]
60. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
